Mount Sinai Leads Global Program Using Stem Cells, Collaborates with The New York Stem Cell Foundation to Accelerate Cures for Alzheimer’s Disease Sam Gandy, MD, PhD, of the Icahn School of Medicine at Mount Sinai is leading an international team of researchers working to reprogram skin cells into brain cells to gain a better understanding of Alzheimer’s disease. As part of the Consortium, Dr. Gandy is collaborating with Scott Noggle, PhD, the NYSCF – Charles Evans Senior Research Fellow for Alzheimer’s Disease and Director of the New York Stem Cell Foundation (NYSCF)’s laboratory in Manhattan. [New York Stem Cell Foundation] Press Release CDI Partners with Buck to Derive and Bank iPSCs Cellular Dynamics International (CDI) announced that the company is opening a facility in Novato, Calif., leasing space from the Buck Institute for Research on Aging (Buck). This opening of a second CDI facility is in response to the company receiving a $16 million grant award from the California Institute of Regenerative Medicine to create and bank human induced pluripotent stem cells (iPSCs). [Buck Institute for Research on Aging] Press Release Retina Institute Japan and Dainippon Sumitomo Pharma Form a Capital Alliance towards the Development of Nobel Prize Winning iPS Cell Technology Retina Institute Japan K.K. (RIJ) and Dainippon Sumitomo Pharma Co., Ltd. (DSP) announced that the two companies signed an agreement that DSP invests into RIJ to discuss alliance to put iPS cell technology to practical use. [Dainippon Sumitomo Pharma Co., Ltd.] Press Release ReNeuron and Cell Therapy Catapult in Landmark Collaboration on New Cell Manufacturing Technologies – First UK Corporate Deal for CT Catapult to Focus on ReNeuron’s Lead Cell Therapy Candidate ReNeuron and the Cell Therapy Catapult announced that they have signed an agreement to work together on new cell therapy manufacturing technologies and assays. [ReNeuron Group plc] Press Release AstraZeneca and Moderna Therapeutics Announce Exclusive Agreement to Develop Pioneering Messenger RNA Therapeuticsâ„¢ in Cardiometabolic Diseases and Cancer AstraZeneca announced an exclusive agreement with Moderna Therapeutics to discover, develop and commercialize pioneering messenger RNA therapeuticsâ„¢ for the treatment of serious cardiovascular, metabolic and renal diseases as well as cancer. [AstraZeneca] Press Release NeoStem Awarded Second Year of NIAID Research Grant for the Development of VSEL Technology for Radiation Exposure NeoStem, Inc. announced that it has been awarded the second year of a two year grant totaling $595,252 for the “Development of Human, Autologous, Pluripotent Very Small Embryonic Like (VSELs) Stem Cells as a Countermeasure to Radiation Threat”, Grant Number 5R43AI098325-02 from the National Institute of Allergy and Infectious Diseases (NIAID), a division of the National Institutes of Health. [NeoStem, Inc.] Press Release Harper Government Announces New Personalized Health Research Projects Across Canada Joy Smith on behalf of the Honorable Leona Aglukkaq, Minister of Health, announced an investment of $13.7 million to support four research projects in Ontario. The announcement was made during a visit to the Children’s Hospital of Eastern Ontario (CHEO) in Ottawa to learn more about a project, under Dr. Kym Boycott’s leadership, that will use new technologies to identify the genes implicated in many rare disorders and test treatment against the identified genes. [CHEO Research Institute] Press Release Regenerative Medicine Company, Eqalix, Announces Grant from Nanotechnology Institute in Philadelphia, Pennsylvania Eqalix has announced they have received a $50,000 grant from the Nanotechnology Institute in Philadelphia Pennsylvania which will facilitate the advancement of the development of its technologies for regenerative medicine. [The Nanotechnology Institute] Press Release ReNeuron Receives Regulatory and Ethical Approvals to Commence Clinical Trial in UK with Stem Cell Therapy Candidate for Critical Limb Ischemia ReNeuron announced that it has received regulatory and ethical approvals to commence a Phase I clinical trial in the UK with its ReN009 stem cell therapy program targeting the major unmet medical need, critical limb ischemia. [ReNeuron Group plc] Press Release Cytori Patents Method of Treating Renal Diseases Using Adipose-Derived Regenerative Cells Cytori Therapeutics received US Patent No. 8,404,229 (the ‘229 patent) for methods of treating renal diseases using adipose-derived regenerative cells (ADRCs). The ‘229 patent covers treatment of a broad range of renal disorders, including acute kidney disease and chronic kidney disease. The ‘229 patent also covers multiple means of delivering the ADRCs, including to the kidney directly, to the renal vasculature or to the renal parenchyma. [Cytori Therapeutics] Press Release |